Trinh Duong
Long-term virological outcome in children on antiretroviral therapy in the UK and Ireland
Duong, Trinh; Judd, Ali; Collins, Intira Jeannie; Doerholt, Katja; Lyall, Hermione; Foster, Caroline; Butler, Karina; Tookey, Pat; Shingadia, Delane; Menson, Esse; Dunn, David T.; Gibb, Di M.; Smyth, Alan R.
Authors
Ali Judd
Intira Jeannie Collins
Katja Doerholt
Hermione Lyall
Caroline Foster
Karina Butler
Pat Tookey
Delane Shingadia
Esse Menson
David T. Dunn
Di M. Gibb
Alan R. Smyth
Abstract
Objective: To assess factors at the start of antiretroviral therapy (ART) associated with long-term virological response in children.
Design: Multicentre national cohort.
Methods: Factors associated with viral load below 400 copies/ml by 12 months and virologic failure among children starting 3/4-drug ART in the UK/Irish Collaborative HIV Paediatric Study were assessed using Poisson models.
Results: Nine hundred and ninety-seven children started ART at a median age of 7.7 years (inter-quartile range 2.9–11.7), 251 (25%) below 3 years: 411 (41%) with efavirenz and two nucleoside reverse transcriptase inhibitors (EFVþ2NRTIs), 264 (26%) with nevirapine and two NRTIs (NVPþ2NRTIs), 119 (12%; 106 NVP, 13 EFV) with non-nucleoside reverse transcriptase inhibitor and three NRTIs (NNRTIþ3NRTIs), and 203 (20%) with boosted protease inhibitor-based regimens. Median follow-up after ART initiation was 5.7 (3.0–8.8) years. Viral load was less than 400 copies/ml by 12 months in 92% [95% confidence interval (CI) 91–94%] of the children. Time to suppression was similar across regimens (P¼0.10), but faster over calendar time, with older age and lower baseline viral load. Three hundred and thirtynine (34%) children experienced virological failure. Although progression to failure varied by regimen (P<0.001) and was fastest for NVPþ2NRTIs regimens, risk after 2 years on therapy was similar for EFVþ2NRTIs and NVPþ2NRTIs, and lowest for NNRTIþ3NRTIs regimens (P-interaction¼0.03). Older age, earlier calendar periods and maternal ART exposure were associated with increased failure risk. Early treatment discontinuation for toxicity occurred more frequently for NVP-based regimens, but 5-year cumulative incidence was similar: 6.1% (95% CI 3.9–8.9%) NVP, 8.3% (95% CI 5.6–11.6) EFV, and 9.8% (95% CI 5.7–15.3%) protease inhibitor-based regimens (P¼0.48).
Conclusion: Viral load suppression by 12 months was high with all regimens. NVPþ3NRTIs regimens were particularly efficacious in the longer term and may be a good alternative to protease inhibitor-based ART in young children.
Citation
Duong, T., Judd, A., Collins, I. J., Doerholt, K., Lyall, H., Foster, C., Butler, K., Tookey, P., Shingadia, D., Menson, E., Dunn, D. T., Gibb, D. M., & Smyth, A. R. (2014). Long-term virological outcome in children on antiretroviral therapy in the UK and Ireland. AIDS, 28(16), https://doi.org/10.1097/QAD.0000000000000438
Journal Article Type | Article |
---|---|
Publication Date | Oct 23, 2014 |
Deposit Date | Feb 15, 2016 |
Publicly Available Date | Feb 15, 2016 |
Journal | AIDS |
Print ISSN | 0269-9370 |
Electronic ISSN | 1473-5571 |
Publisher | Lippincott, Williams & Wilkins |
Peer Reviewed | Peer Reviewed |
Volume | 28 |
Issue | 16 |
DOI | https://doi.org/10.1097/QAD.0000000000000438 |
Keywords | antiretroviral therapy, children, HIV, UK/Ireland, virological outcome |
Public URL | https://nottingham-repository.worktribe.com/output/737706 |
Publisher URL | http://journals.lww.com/aidsonline/pages/articleviewer.aspx?year=2014&issue=10230&article=00008&type=abstract |
Files
Duong AIDS 2014 Long term virological outcome children.pdf
(523 Kb)
PDF
Copyright Statement
Copyright information regarding this work can be found at the following address: http://creativecommons.org/licenses/by-nc-nd/4.0
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search